Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.

RU-24969

  Cat. No.:  DC23941   Featured
Chemical Structure
66611-26-5
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
A potent, selective agonist of 5-HT1A and 5-HT1B receptors, with preference for 5-HT1B.
Cas No.: 66611-26-5
Chemical Name: RU 24969
Synonyms: 1H-Indole, 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-;5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-Indole;5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole;RU24969;RU-24969;Tocris-0912;RU 24969;3-(1,2,3,6-tetrahydropyridin-4-yl)-5-methoxy-1H-indole;CHEBI:92005;5-methoxy-3-(1,2,3,6-tetrahydropyridine-4-yl)-1H-indole;NCGC00024867-01;5-Methoxy 3-(1,2,3,6-tetrahydro-4-pyridinyl)1H indole;2ISE72RACC;5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole;NCGC00024867-02;UNII-2ISE72RACC;BPBio1_000177;GTPL23;AKOS005135871;74163-68-1;DTXSID40276045;SCHEMBL2359264;Q7277958;RU-24,969;5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridyl)-1h-indole;PDSP1_001617;PDSP2_001607;CHEMBL18785;66611-26-5;FT-0745673;CAS_108028;L001328;HY-16688;PDSP1_001623;Z385446106;SR-01000597981;NSC_108028;PDSP2_001601;BDBM81498;CS-3218;EN300-39806;KRVMLPUDAOWOGN-UHFFFAOYSA-N;5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole;A914233;U-24969;5-Methoxy-3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole;5-Methoxy-3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H-indole(RU-24969);AB00698348-04;SR-01000597981-1;EX-A4097;Biomol-NT_000116
SMILES: COC1=CC=C2C(C(C3=CCNCC3)=CN2)=C1
Formula: C14H16N2O
M.Wt: 228.28964
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: A potent, selective agonist of 5-HT1A and 5-HT1B receptors, with preference for 5-HT1B; inhibited the rate of synthesis of 5-HT in rat brain by about 50% (10mg/kg)
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC31074 Isopropyl myristate Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868 AZ14133346 AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865 TI17 ​​TI17​​ represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816 Nisoxetine Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641 GENZ-644282 TFA salt Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325 PSMA-617 TFA PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202 Fosaprepitant free acid Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748 O4I4 O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684 ZH8667 ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646 EB-PSMA-617 EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.
X